82
64
Growth Score
-6 pts
Heat Score
-21 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
451049
Nervosave Therapeutics develops gene therapies for peripheral nerve diseases like CMT1 and CMT4 using AAV9 vectors.
- Cathy Barret Beaumard: Co-Founder, General Manager & Quality Officer
- Nicolas Tricaud: Co-Founder, CEO & CSO
About the Company
Nervosave Therapeutics develops a platform of local gene therapies aimed at slowing, stopping, and reversing a broad range of diseases involving peripheral nerves. The company focuses on conditions such as Charcot-Marie-Tooth disease types 1 and 4 (CMT1 and CMT4). Their technology utilizes AAV9 vectors for local delivery in nerves, enabling
specific transduction of myelinating Schwann cells. This approach targets the underlying causes of nerve demyelination, offering potential therapeutic benefits for traumatic and diabetic neuropathies as well.
